Table 6.
Base case results: Distribution of patients across the health states
| Base case scenario | FDC tablet solifenacin 6 mg + TOCAS | Tolterodine + tamsulosin |
|---|---|---|
| Patient in HS1 | 41.46% | 32.76% |
| Patient in HS2 | 23.56% | 17.76% |
| Patient on second-line treatment | 4.30% | 6.50% |
| Patient withdrawn | 14.60% | 20.75% |
| Patient who discontinued treatment | 7.71% | 10.57% |
| Patient in post-surgery | 6.89% | 10.18% |
| Dead patient | 1.48% | 1.48% |
FDC, fixed-dose combination; HS1, Response health state; HS2, No response health state; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.